<DOC>
	<DOC>NCT00791947</DOC>
	<brief_summary>This is a phase II prospective non-randomised clinical trial in newly diagnosed and previously untreated adult patients in the age range 18-60 (67) years with peripheral T-cell lymphoma. The treatment schedule will consist of three phases: induction and high-dose consolidation, followed by autologous stem cell rescue. There will be two different induction schedules: one for patients in the age range 18-60 years and one for patients aged over 60 years.</brief_summary>
	<brief_title>A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<criteria>Previously untreated patients with newly diagnosed peripheral Tcell lymphoma of all stages. However, patients with nodal stage IA nonbulky disease (&lt;10cm) can be treated individually at the discretion of the responsible physician. Following histologic subtypes (WHO classification) are eligible for inclusion in the study: Peripheral Tcell lymphomas, unspecified Angioimmunoblastic Tcell lymphoma NK/T nasaltype Tcell lymphoma Enteropathytype Tcell lymphoma Primary systemic, alknegative anaplastic large cell lymphoma (Tor null phenotype) Hepatosplenic Tcell lymphoma Subcutaneous panniculitislike Tcell lymphoma NB: Patients should not enter the treatment program before confirmation of the histopathological diagnosis by the referral center pathologist Age 1860 years. Patients in the age range 6167 years may be included in this protocol at discretion of the treating physician. formed consent based on oral and written patient information (Appendix I) Primary cutaneous Tor nullcell anaplastic largecell lymphoma Alkpositive, primary systemic Tor nullcell anaplastic largecell lymphoma WHO Performance Status grade 4 (Appendix II) Patients with severe cardiac (i.e. severe heart failure requiring symptomatic treatment or a cardiac ejection fraction of less than 45%), pulmonary, neurologic, psychiatric, renal, hepatic or metabolic disease. Pregnancy. N.B: Women of childbearing potential should be strongly advised to apply appropriate contraceptive precautions during the entire treatment period. Patients with concomitant malignancies except for nonmelanoma skin tumors or stage 0 (in situ) cervical carcinoma. Patients with seropositivity for the human immunodeficiency virus. Patients with other active and therapeutically uncontrolled infection. Psychological, familial, social or other condition/s potentially hampering compliance and followup.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>